Research output: Contribution to journal › Article › peer-review
Chronic post-COVID-19 syndrome and chronic fatigue syndrome : Is there a role for extracorporeal apheresis? / Bornstein, Stefan R.; Voit-Bak, Karin; Donate, Timo; Rodionov, Roman N.; Gainetdinov, Raul R.; Tselmin, Sergey; Kanczkowski, Waldemar; Müller, Gregor M.; Achleitner, Martin; Wang, Jun; Licinio, Julio; Bauer, Michael; Young, Allan H.; Thuret, Sandrine; Bechmann, Nicole; Straube, Richard.
In: Molecular Psychiatry, 2021.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Chronic post-COVID-19 syndrome and chronic fatigue syndrome
T2 - Is there a role for extracorporeal apheresis?
AU - Bornstein, Stefan R.
AU - Voit-Bak, Karin
AU - Donate, Timo
AU - Rodionov, Roman N.
AU - Gainetdinov, Raul R.
AU - Tselmin, Sergey
AU - Kanczkowski, Waldemar
AU - Müller, Gregor M.
AU - Achleitner, Martin
AU - Wang, Jun
AU - Licinio, Julio
AU - Bauer, Michael
AU - Young, Allan H.
AU - Thuret, Sandrine
AU - Bechmann, Nicole
AU - Straube, Richard
N1 - Publisher Copyright: © 2021, The Author(s).
PY - 2021
Y1 - 2021
N2 - As millions of patients have been infected by SARS-CoV-2 virus a vast number of individuals complain about continuing breathlessness and fatigue even months after the onset of the disease. This overwhelming phenomenon has not been well defined and has been called “post-COVID syndrome” or “long-COVID” [1]. There are striking similarities to myalgic encephalomyelitis also called chronic fatigue syndrome linked to a viral and autoimmune pathogenesis. In both disorders neurotransmitter receptor antibodies against ß-adrenergic and muscarinic receptors may play a key role. We found similar elevation of these autoantibodies in both patient groups. Extracorporeal apheresis using a special filter seems to be effective in reducing these antibodies in a significant way clearly improving the debilitating symptoms of patients with chronic fatigue syndrome. Therefore, such a form of neuropheresis may provide a promising therapeutic option for patients with post-COVID-19 syndrome. This method will also be effective when other hitherto unknown antibodies and inflammatory mediators are involved.
AB - As millions of patients have been infected by SARS-CoV-2 virus a vast number of individuals complain about continuing breathlessness and fatigue even months after the onset of the disease. This overwhelming phenomenon has not been well defined and has been called “post-COVID syndrome” or “long-COVID” [1]. There are striking similarities to myalgic encephalomyelitis also called chronic fatigue syndrome linked to a viral and autoimmune pathogenesis. In both disorders neurotransmitter receptor antibodies against ß-adrenergic and muscarinic receptors may play a key role. We found similar elevation of these autoantibodies in both patient groups. Extracorporeal apheresis using a special filter seems to be effective in reducing these antibodies in a significant way clearly improving the debilitating symptoms of patients with chronic fatigue syndrome. Therefore, such a form of neuropheresis may provide a promising therapeutic option for patients with post-COVID-19 syndrome. This method will also be effective when other hitherto unknown antibodies and inflammatory mediators are involved.
KW - COVID-19
KW - SYSTEM
UR - http://www.scopus.com/inward/record.url?scp=85108103059&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/a04702dd-1238-37e4-b5c3-1de43b9981f7/
U2 - 10.1038/s41380-021-01148-4
DO - 10.1038/s41380-021-01148-4
M3 - Article
AN - SCOPUS:85108103059
JO - Molecular Psychiatry
JF - Molecular Psychiatry
SN - 1359-4184
ER -
ID: 87887931